Milestone Pharmaceuticals Enrolls First Canadian Patient in Phase 3 Etripamil Trial

Milestone Pharmaceuticals Inc. (MIST) said on September 26, 2026, that the first Canadian patient has been enrolled in the Phase 3 ReVeRA-301 trial evaluating its Etripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks the company's first Canadian site participation in the late-stage study, expanding the trial's geographic footprint. Financial terms and enrollment targets were not disclosed. Montreal-based Milestone is developing Etripamil as a self-administered nasal spray for paroxysmal supraventricular tachycardia and related cardiac arrhythmias. The company has not announced a timeline for top-line data from the trial.